AstraZeneca is stepping up its pursuit of a rare disease market targeted by Alnylam and Pfizer. Having entered the ATTR space through its takeover of Alexion, AstraZeneca is paying $30 million for…
Alnylam’s Maraganore plots his next move. Eikon Therapeutics adds six to its executive roster. Exelixis taps Merck veteran as CMO as it pivots east.
Three years after launching a Class I recall of some of its StealthStation surgical navigation software, Medtronic has once again received the FDA’s most serious classification for yet another recall…
The new cartridge-based, nasal swab test will be compatible with the company’s point-of-care reader.
In 2021 biotech had a median deal of $10 million and an average deal of $36.9 million, according to the report by PitchBook Data. Comparatively, medtech locked in an median of $3.9 million and $12.6…
Dr. Namrata Rastogi Dr Namrata Rastogi is a Primary Care Physician and Healthtech Investor. She angel invests in early stage founders in the US and UK. Her thesis is around value-based care, health equity, improving efficiency of care delivery and population health management. https://medcitynews.com/author/nrastogi
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could…
Health IT, MedCity Influencers Health IT predictions for 2020: Trust takes center stage By Tom Skelton Looking forward to 2020, the most important new voice on this topic will be the consumer. Will there be massive consumer-directed outflows of data from healthcare incumbents to new entrants? Data security and privacy will be debated vigorously by …
It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new biotech companies. Here’s a look at the IPOs of Amylyx…
The CEO of Surescripts believes we are living in an unpredictable world coupled with an explosion of innovation that aims to solve challenges like the cost of medications, administrative inefficiency…
